WO2011044538A1 - Analogues d'aminoglycoside antibactériens - Google Patents

Analogues d'aminoglycoside antibactériens Download PDF

Info

Publication number
WO2011044538A1
WO2011044538A1 PCT/US2010/052109 US2010052109W WO2011044538A1 WO 2011044538 A1 WO2011044538 A1 WO 2011044538A1 US 2010052109 W US2010052109 W US 2010052109W WO 2011044538 A1 WO2011044538 A1 WO 2011044538A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
mmol
hydrogen
reaction
yield
Prior art date
Application number
PCT/US2010/052109
Other languages
English (en)
Other versions
WO2011044538A9 (fr
Inventor
James Bradley Aggen
Paola Dozzo
Adam Aaron Goldblum
Darin James Hildebrandt
Timothy Robert Kane
Micah James Gliedt
Martin Sheringham Linsell
Original Assignee
Achaogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Achaogen, Inc. filed Critical Achaogen, Inc.
Publication of WO2011044538A1 publication Critical patent/WO2011044538A1/fr
Publication of WO2011044538A9 publication Critical patent/WO2011044538A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/22—Cyclohexane rings, substituted by nitrogen atoms
    • C07H15/222—Cyclohexane rings substituted by at least two nitrogen atoms
    • C07H15/226—Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings
    • C07H15/228—Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings attached to adjacent ring-carbon atoms of the cyclohexane rings
    • C07H15/232—Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings attached to adjacent ring-carbon atoms of the cyclohexane rings with at least three saccharide radicals in the molecule, e.g. lividomycin, neomycin, paromomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • the present invention is directed to novel aminoglycoside compounds, and methods for their preparation and use as therapeutic or prophylactic agents. Description of the Related Art
  • RNA which serves as a messenger between DNA and proteins, was thought to be an entirely flexible molecule without significant structural complexity. Recent studies have revealed a surprising intricacy in RNA structure. RNA has a structural complexity rivaling proteins, rather than simple motifs like DNA. Genome sequencing reveals both the sequences of the proteins and the mRNAs that encode them. Since proteins are synthesized using an RNA template, such proteins can be inhibited by preventing their production in the first place by interfering with the translation of the mRNA. Since both proteins and the RNAs are potential drug targeting sites, the number of targets revealed from genome sequencing efforts is effectively doubled. These observations unlock a new world of opportunities for the pharmaceutical industry to target RNA with small molecules.
  • Proteins can be extremely difficult to isolate and purify in the appropriate form for use in assays for drug screening. Many proteins require post-translational modifications that occur only in specific cell types under specific conditions. Proteins fold into globular domains with hydrophobic cores and hydrophilic and charged groups on the surface. Multiple subunits frequently form complexes, which may be required for a valid drug screen. Membrane proteins usually need to be embedded in a membrane to retain their proper shape. The smallest practical unit of a protein that can be used in drug screening is a globular domain.
  • RNAs are essentially equivalent in their solubility, ease of synthesis or use in assays.
  • the physical properties of RNAs are independent of the protein they encode. They may be readily prepared in large quantity through either chemical or enzymatic synthesis and are not extensively modified in vivo.
  • RNA the smallest practical unit for drug binding is the functional subdomain.
  • a functional subdomain in RNA is a fragment that, when removed from the larger RNA and studied in isolation, retains its biologically relevant shape and protein or RNA-binding properties. The size and composition of RNA functional subdomains make them accessible by enzymatic or chemical synthesis.
  • RNA subdomains The structural biology community has developed significant experience in identification of functional RNA subdomains in order to facilitate structural studies by techniques such as NMR spectroscopy. For example, small analogs of the decoding region of 16S rR A (the A-site) have been identified as containing only the essential region, and have been shown to bind antibiotics in the same fashion as the intact ribosome.
  • RNA binding sites on RNA are hydrophilic and relatively open as compared to proteins.
  • the potential for small molecule recognition based on shape is enhanced by the deformability of RNA.
  • the binding of molecules to specific RNA targets can be determined by global conformation and the distribution of charged, aromatic, and hydrogen bonding groups off of a relatively rigid scaffold. Properly placed positive charges are believed to be important, since long-range electrostatic interactions can be used to steer molecules into a binding pocket with the proper orientation. In structures where nucleobases are exposed, stacking interactions with aromatic functional groups may contribute to the binding interaction.
  • the major groove of RNA provides many sites for specific hydrogen bonding with a ligand.
  • RNA RNA molecules
  • aromatic N7 nitrogen atoms of adenosine and guanosine the 04 and 06 oxygen atoms of uridine and guanosine
  • amines of adenosine and cytidine The rich structural and sequence diversity of RNA suggests to us that ligands can be created with high affinity and specificity for their target.
  • Certain small molecules can bind and block essential functions of RNA.
  • examples of such molecules include the aminoglycoside antibiotics and drugs such as erythromycin which binds to bacterial rRNA and releases peptidyl-tRNA and mRNA.
  • Aminoglycoside antibiotics have long been known to bind RNA. They exert their antibacterial effects by binding to specific target sites in the bacterial ribosome. For the structurally related antibiotics neamine, ribostamycin, neomycin B, and paromomycin, the binding site has been localized to the A-site of the prokaryotic 16S ribosomal decoding region RNA (see Moazed, D.; Noller, H.F., Nature, 1987, 327, 389).
  • Binding of aminoglycosides to this RNA target interferes with the fidelity of mRNA translation and results in miscoding and truncation, leading ultimately to bacterial cell death (see Alper, P.B.; Hendrix, M.; Sears, P.; Wong, C, J. Am. Chem. Soc, 1998, 120, 1965).
  • RNA-binding antibacterial drugs There is a need in the art for new chemical entities that work against bacteria with broad-spectrum activity. Perhaps the biggest challenge in discovering RNA-binding antibacterial drugs is identifying vital structures common to bacteria that can be disabled by small molecule drug binding. A challenge in targeting RNA with small molecules is to develop a chemical strategy which recognizes specific shapes of RNA. There are three sets of data that provide hints on how to do this: natural protein interactions with RNA, natural product antibiotics that bind RNA, and man-made R As (aptamers) that bind proteins and other molecules. Each data set, however, provides different insights to the problem.
  • RNA targets in the ribosome one of the most ancient and conserved targets in bacteria. Since antibacterial drugs are desired to be potent and have broad-spectrum activity, these ancient processes, fundamental to all bacterial life, represent attractive targets. The closer we get to ancient conserved functions the more likely we are to find broadly conserved RNA shapes. It is important to also consider the shape of the equivalent structure in humans, since bacteria were unlikely to have considered the therapeutic index of their RNAs while evolving them.
  • antibiotics include the aminoglycosides, such as, kirromycin, neomycin, paromomycin, thiostrepton, and many others. They are very potent, bactericidal compounds that bind RNA of the small ribosomal subunit. The bactericidal action is mediated by binding to the bacterial RNA in a fashion that leads to misreading of the genetic code. Misreading of the code during translation of integral membrane proteins is thought to produce abnormal proteins that compromise the barrier properties of the bacterial membrane.
  • Antibiotics are chemical substances produced by various species of microorganisms (bacteria, fungi, actinomycetes) that suppress the growth of other microorganisms and may eventually destroy them.
  • antibiotics common usage often extends the term antibiotics to include synthetic antibacterial agents, such as the sulfonamides, and quinolines, that are not products of microbes.
  • the number of antibiotics that have been identified now extends into the hundreds, and many of these have been developed to the stage where they are of value in the therapy of infectious diseases.
  • Antibiotics differ markedly in physical, chemical, and pharmacological properties, antibacterial spectra, and mechanisms of action. In recent years, knowledge of molecular mechanisms of bacterial, fungal, and viral replication has greatly facilitated rational development of compounds that can interfere with the life cycles of these microorganisms.
  • the present invention is directed to novel aminoglycoside compounds, having antibacterial activity, including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, and the use of such compounds in the treatment of bacterial infections.
  • each Ri and R2 is, independently, hydrogen or an amino protecting group
  • each R3 is, independently, hydrogen or a hydroxyl protecting group
  • each R4, R 5 , R 7 and Rg is, independently, hydrogen or Ci-Ce alkyl optionally substituted with one or more halogen, hydroxyl or amino;
  • each 3 ⁇ 4 is, independently, hydrogen, halogen, hydroxyl, amino or Ci-Ce alkyl
  • R4 and R 5 together with the atoms to which they are attached can form a heterocyclic ring having from 4 to 6 ring atoms, or R 5 and one Ri together with the atoms to which they are attached can form a heterocyclic ring having from 3 to 6 ring atoms, or R4 and one R3 ⁇ 4 together with the atoms to which they are attached can form a carbocyclic ring having from 3 to 6 ring atoms, or R 7 and Rs together with the atom to which they are attached can form a heterocyclic ring having from 3 to 6 ring atoms; each R is, independently, hydrogen, hydroxyl, amino or C1-C6 alkyl optionally substituted with one or more halogen, hydroxyl or amino;
  • each Rio is, independently, hydrogen, halogen, hydroxyl, amino or C1-C alkyl
  • R 9 and one io together with the atoms to which they are attached can form a heterocyclic ring having from 3 to 6 ring atoms;
  • each R11 and R [2 is, independently, C1-C6 alkyl or substituted CpCe alkyl;
  • each n is, independently, an integer from 0 to 4.
  • Zi is hydrogen, halogen or -OR3.
  • Qi is -NR1R2, -NR1R11, -NRnRu or -OR 3 ;
  • Q2 is optionally substituted alkyl
  • each Rj and R2 is, independently, hydrogen or an amino protecting group
  • each R 3 is, independently, hydrogen or a hydroxyl protecting group
  • each R4, R 5 , R 7 and Rg is, independently, hydrogen or Ci-Ce alkyl optionally substituted with one or more halogen, hydroxyl or amino;
  • each Re is, independently, hydrogen, halogen, hydroxyl, amino or Ci-Ce alkyl; or 4 and R5 together with the atoms to which they are attached can form a heterocyclic ring having from 4 to 6 ring atoms, or R s and one Re together with the atoms to which they are attached can form a heterocyclic ring having from 3 to 6 ring atoms, or 4 and one R « together with the atoms to which they are attached can form a carbocyclic ring having from 3 to 6 ring atoms, or R7 and Rs together with the atom to which they are attached can form a heterocyclic ring having from 3 to 6 ring atoms;
  • each R is, independently, hydrogen, hydroxyl, amino or C1-C6 alkyl optionally substituted with one or more halogen, hydroxyl or amino;
  • each Rio is, independently, hydrogen, halogen, hydroxyl, amino or Ci-Ce alkyl
  • R 9 and one Rio together with the atoms to which they are attached can form a heterocyclic ring having from 3 to 6 ring atoms;
  • each R11 and R12 is, independently, Ci-Q alkyl or substituted C1-C6 alkyl;
  • each n is, independently, an integer from 0 to 4.
  • Z] is hydrogen, halogen or -OR3.
  • a pharmaceutical composition comprising a compound having structure (I) or (II), or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable carrier, diluent or excipient.
  • a method of using a compound having structure (I) or (II) in therapy is provided.
  • the present invention provides a method of treating a bacterial infection in a mammal comprising administering to a mammal in need thereof an effective amount of a compound having structure (I) or (II), or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof.
  • the present invention provides a method of treating a bacterial infection in a mammal comprising administering to a mammal in need thereof an effective amount of a pharmaceutical composition comprising a compound having structure (I) or (II), or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable carrier, diluent or excipient.
  • Amino refers to the -N3 ⁇ 4 radical.
  • Niro refers to the - O2 radical.
  • Alkyl refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, which is saturated or unsaturated (i.e., contains one or more double and/or triple bonds), having from one to twelve carbon atoms (C1-C12 alkyl), preferably one to eight carbon atoms (Ci-Cs alkyl) or one to six carbon atoms (Ci-C 6 alkyl), and which is attached to the rest of the molecule by a single bond, e.g.
  • an alkyl group may be optionally substituted.
  • Alkylene or “alkylene chain” refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, which is saturated or unsaturated (i.e. , contains one or more double and/or triple bonds), and having from one to twelve carbon atoms, e.g., methylene, ethylene, propylene, n-butylene, ethenylene, propenylene, w-butenylene, propynylene, w-butynylene, and the like.
  • the alkylene chain is attached to the rest of the molecule through a single or double bond and to the radical group through a single or double bond.
  • the points of attachment of the alkylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkylene chain may be optionally substituted.
  • Alkoxy refers to a radical of the formula -ORa where Ra is an alkyl radical as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, an alkoxy group may be optionally substituted.
  • Alkylamino refers to a radical of the formula -NHRa or -NRaR a where each R a is, independently, an alkyl radical as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, an alkylamino group may be optionally substituted.
  • Thioalkyl refers to a radical of the formula -SR where Ra is an alkyl radical as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, a thioalkyl group may be optionally substituted.
  • Aryl refers to a hydrocarbon ring system radical comprising hydrogen, 6 to 18 carbon atoms and at least one aromatic ring. For purposes of this invention, the aryl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems.
  • Aryl radicals include, but are not limited to, aryl radicals derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, as-indacene, s-indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene.
  • Aralkyl refers to a radical of the formula -Rb-Rc where 3 ⁇ 4 is an alkylene chain as defined above and Ro is one or more aryl radicals as defined above, for example, benzyl, diphenylmethyl and the like. Unless stated otherwise specifically in the specification, an aralkyl group may be optionally substituted.
  • Cycloalkyl or “carbocyclic ring” refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, which may include fused or bridged ring systems, having from three to fifteen carbon atoms, preferably having from three to ten carbon atoms, and which is saturated or unsaturated and attached to the rest of the molecule by a single bond.
  • Monocyclic radicals include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
  • Polycyclic radicals include, for example, adamantyl, norbornyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like. Unless otherwise stated specifically in the specification, a cycloalkyl group may be optionally substituted.
  • Cycloalkylalkyl refers to a radical of the formula -Rb d where 3 ⁇ 4 is an alkylene chain as defined above and R g is a cycloalkyl radical as defined above. Unless stated otherwise specifically in the specification, a cycloalkylalkyl group may be optionally substituted.
  • fused refers to any ring structure described herein which is fused to an existing ring structure in the compounds of the invention.
  • the fused ring is a heterocyclyl ring or a heteroaryl ring
  • any carbon atom on the existing ring structure which becomes part of the fused heterocyclyl ring or the fused heteroaryl ring may be replaced with a nitrogen atom.
  • Halo or halogen refers to bromo, chloro, fluoro or iodo.
  • Haloalkyl refers to an alkyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., trifluoromethyl, difluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, and the like. Unless stated otherwise specifically in the specification, a haloalkyl group may be optionally substituted.
  • Heterocyclyl or “heterocyclic ring” refers to a stable 3- to
  • the heterocyclyl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heterocyclyl radical may be optionally oxidized; the nitrogen atom may be optionally quaternized; and the heterocyclyl radical may be partially or fully saturated.
  • heterocyclyl radicals include, but are not limited to, dioxolanyl, thienyl[l,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, j octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxoxo
  • Heterocyclylalkyl refers to a radical of the formula -RbRe where 3 ⁇ 4 is an alkylene chain as defined above and 3 ⁇ 4 is a heterocyclyl radical as defined above, and if the heterocyclyl is a nitrogen-containing heterocyclyl, the heterocyclyl may be attached to the alkyl radical at the nitrogen atom. Unless stated otherwise specifically in the specification, a heterocyclylalkyl group may be optionally substituted.
  • Heteroaryl refers to a 5- to 14-membered ring system radical comprising hydrogen atoms, one to thirteen carbon atoms, one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, and at least one aromatic ring.
  • the heteroaryl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heteroaryl radical may be optionally oxidized; the nitrogen atom may be optionally quaternized.
  • Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzodioxolyl, benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[£>][l,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzotriazolyl, benzo[4,6]imidazo[l,2-a]pyridinyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothiophenyl
  • V-heteroaryl refers to a heteroaryl radical as defined above containing at least one nitrogen and where the point of attachment of the heteroaryl radical to the rest of the molecule is through a nitrogen atom in the heteroaryl radical. Unless stated otherwise specifically in the specification, an iV-heteroaryl group may be optionally substituted.
  • Heteroarylalkyl refers to a radical of the formula -R b R f where 3 ⁇ 4 is an alkylene chain as defined above and R f is a heteroaryl radical as defined above. Unless stated otherwise specifically in the specification, a heteroarylalkyl group may be optionally substituted.
  • substituted means any of the above groups (i.e., alkyl, alkylene, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, iV-heteroaryl and/or heteroarylalkyl) wherein at least one hydrogen atom is replaced by a bond to a non-hydrogen atoms such as, but not limited to: a halogen atom such as F, CI, Br, and I; an oxygen atom in groups such as hydroxyl groups, alkoxy groups, and ester groups; a sulfur atom in groups such as thiol groups, thioalkyl groups, sulfone groups, sulfonyl groups, and sulfoxide groups; a nitrogen atom in
  • Substituted also means any of the above groups in which one or more hydrogen atoms are replaced by a higher-order bond (e.g., a double- or triple-bond) to a heteroatom such as oxygen in oxo, carbonyl, carboxyl, and ester groups; and nitrogen in groups such as imines, oximes, hydrazones, and nitriles.
  • a higher-order bond e.g., a double- or triple-bond
  • nitrogen in groups such as imines, oximes, hydrazones, and nitriles.
  • Rg and R h are the same or different and independently hydrogen, alkyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, iV-heteroaryl and/or heteroarylalkyl.
  • Substituted further means any of the above groups in which one or more hydrogen atoms are replaced by a bond to an amino, cyano, hydroxyl, imino, nitro, oxo, thioxo, halo, alkyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, 5 haloalkyl, heterocyclyl, iV-heterocyclyl, heterocyclylalkyl, heteroaryl, iV-heteroaryl and/or heteroarylalkyl group.
  • each of the foregoing substituents may also be optionally substituted with one or more of the above substituents.
  • protecting group refers to a labile chemical moiety which is known in the art to protect reactive groups including without limitation,
  • protecting groups Hydroxyl and amino groups which protected with a protecting group are referred to herein as “protected hydroxyl groups” and “protected amino groups”, respectively.
  • Protecting groups are typically used selectively and or orthogonally to protect sites during reactions at other reactive sites and can then be removed to leave the unprotected
  • hydroxyl protecting groups include, but are not limited to, t-butyl, t-butoxymethyl, methoxymethyl, tetrahydropyranyl, 1-ethoxyethyl, l-(2- chloroethoxy)ethyl, 2-trimethylsilylethyl, p-chlorophenyl, 2,4-dinitrophenyl, benzyl, 2,6-dichlorobenzyl, diphenylmethyl, p-nitrobenzyl, triphenylmethyl, trimethylsilyl, triethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl (TBDPS), triphenylsilyl,
  • amino protecting groups include, but are not limited to, carbamate- protecting groups, such as 2-trimethylsilylethoxycarbonyl (Teoc), l-methyl-l-(4- biphenylyl)ethoxycarbonyl (Bpoc), t-butoxycarbonyl (BOC), allyloxycarbonyl (Alloc), 9-fluorenylmethyloxycarbonyl (Fmoc), and benzyloxycarbonyl (Cbz); amide protecting groups, such as formyl, acetyl, trihaloacetyl, benzoyl, and nitrophenylacetyl; sulfonamide-protecting groups, such as 2-nitrobenzenesulfonyl; and imine and cyclic imide protecting groups, such as phthalimido and dithiasuccinoyl.
  • carbamate- protecting groups such as 2-trimethylsilylethoxycarbonyl (Teoc), l-methyl-l-(4- bipheny
  • Prodrug is meant to indicate a compound that may be converted under physiological conditions or by solvolysis to a biologically active compound of the invention.
  • prodrug refers to a metabolic precursor of a compound of the invention that is pharmaceutically acceptable.
  • a prodrug may be inactive when administered to a subject in need thereof, but is converted in vivo to an active compound of the invention.
  • Prodrugs are typically rapidly transformed in vivo to yield the parent compound of the invention, for example, by hydrolysis in blood.
  • the prodrug compound often offers advantages of solubility, tissue compatibility or delayed release in a mammalian organism (see, Bundgard, H., Design of Prodrugs (1985), pp. 7-9, 21-24 (Elsevier, Amsterdam)).
  • prodrugs are provided in Higuchi, T., et al., A.C.S. Symposium Series, Vol. 14, and in Bioreversible Carriers in Drug Design, Ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.
  • prodrug is also meant to include any covalently bonded carriers, which release the active compound of the invention in vivo when such prodrug is administered to a mammalian subject.
  • Prodrugs of a compound of the invention may be prepared by modifying functional groups present in the compound of the invention in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound of the invention.
  • Prodrugs include compounds of the invention wherein a hydroxy, amino or mercapto group is bonded to any group that, when the prodrug of the compound of the invention is administered to a mammalian subject, cleaves to form a free hydroxy, free amino or free mercapto group, respectively.
  • Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol or amide derivatives of amine functional groups in the compounds of the invention and the like.
  • the invention disclosed herein is also meant to encompass all 5 pharmaceutically acceptable compounds of structure (I) or (II) being isotopically- labelled by having one or more atoms replaced by an atom having a different atomic mass or mass number.
  • isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such as 2 H, 3 ⁇ 4 U C, 13 C, 14 C, 13 N, 15 N, 15 0, l7 0, 18 0, 31 P,
  • radiolabelled compounds 10 32 P, 3 S, 18 F, 36 C1, 123 I, and 125 I, respectively.
  • These radiolabelled compounds could be useful to help determine or measure the effectiveness of the compounds, by characterizing, for example, the site or mode of action, or binding affinity to pharmacologically important site of action.
  • Certain isotopically-labelled compounds of structure (I) or (II), for example, those incorporating a radioactive isotope, are useful in
  • radioactive isotopes tritium i.e.
  • 25 can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the Preparations and Examples as set out below using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.
  • the invention includes compounds produced by a process comprising administering a compound of this invention to a mammal for a period of time sufficient to yield a metabolic product thereof.
  • Such products are typically identified by administering a radiolabelled compound of the invention in a detectable dose to an animal, such as rat, mouse, guinea pig, monkey, or to human, allowing sufficient time for metabolism to occur, and isolating its conversion products from the urine, blood or other biological samples.
  • Solid compound and “stable structure” are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
  • “Mammal” includes humans and both domestic animals such as laboratory animals and household pets (e.g., cats, dogs, swine, cattle, sheep, goats, horses, rabbits), and non-domestic animals such as wildlife and the like.
  • Optional or “optionally” means that the subsequently described event of circumstances may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not.
  • optionally substituted aryl means that the aryl radical may or may not be substituted and that the description includes both substituted aryl radicals and aryl radicals having no substitution.
  • “Pharmaceutically acceptable carrier, diluent or excipient” includes without limitation any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier which has been approved by the United States Food and Drug Administration as being acceptable for use in humans or domestic animals.
  • “Pharmaceutically acceptable salt” includes both acid and base addition salts.
  • “Pharmaceutically acceptable acid addition salt” refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as, but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as, but not limited to, acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-l,2-disulfonic
  • “Pharmaceutically acceptable base addition salt” refers to those salts which retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared from addition of an inorganic base or an organic base to the free acid. Salts derived from inorganic bases include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Preferred inorganic salts are the ammonium, sodium, potassium, calcium, and magnesium salts.
  • Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, deanol, 2-dimethylaminoethanol,
  • 2-diethylaminoethanol dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, benetharaine, benzathine, ethylenediamine, glucosamine, methylglucamine, theobromine, triethanolamine, tromethamine, purines, piperazine, piperidine, iV-ethylpiperidine, polyamine resins and the like.
  • Particularly preferred organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline and caffeine.
  • solvate refers to an aggregate that comprises one or more molecules of a compound of the invention with one or more molecules of solvent.
  • the solvent may be water, in which case the solvate may be a hydrate.
  • the solvent may be an organic solvent.
  • the compounds of the present invention may exist as a hydrate, including a monohydrate, dihydrate, hemihydrate, sesquihydrate, trihydrate, tetrahydrate and the like, as well as the corresponding solvated forms.
  • the compound of the invention may be true solvates, while in other cases, the compound of the invention may merely retain adventitious water or be a mixture of water plus some adventitious solvent.
  • a “pharmaceutical composition” refers to a formulation of a compound of the invention and a medium generally accepted in the art for the delivery of the biologically active compound to mammals, e.g., humans.
  • a medium includes all pharmaceutically acceptable carriers, diluents or excipients therefor.
  • Effective amount refers to that amount of a compound of the invention which, when administered to a mammal, preferably a human, is sufficient to effect treatment, as defined below, of a bacterial infection in the mammal, preferably a human.
  • the amount of a compound of the invention which constitutes a “therapeutically effective amount” will vary depending on the compound, the condition and its severity, the manner of administration, and the age of the mammal to be treated, but can be determined routinely by one of ordinary skill in the art having regard to his own knowledge and to this disclosure.
  • Treating or “treatment” as used herein covers the treatment of the disease or condition of interest in a mammal, preferably a human, having the disease or condition of interest, and includes:
  • disease and “condition” may be used interchangeably or may be different in that the particular malady or condition may not have a known causative agent (so that etiology has not yet been worked out) and it is therefore not yet recognized as a disease but only as an undesirable condition or syndrome, wherein a more or less specific set of symptoms have been identified by clinicians.
  • the compounds of the invention, or their pharmaceutically acceptable salts may contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (5)- or, as (D)- or (L)- for amino acids.
  • the present invention is meant to include all such possible isomers, as well as their racemic and optically pure forms.
  • Optically active (+) and (-), (R)- and (5)-, or (D)- and (L)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, for example, chromatography and fractional crystallization.
  • stereoisomer refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures, which are not interchangeable.
  • the present invention contemplates various stereoisomers and mixtures thereof and includes “enantiomers”, which refers to two stereoisomers whose molecules are nonsuperimposeable mirror images of one another.
  • a “tautomer” refers to a proton shift from one atom of a molecule to another atom of the same molecule.
  • the present invention includes tautomers of any said compounds.
  • compounds having antibacterial activity are provided, the compounds having the following structure (I):
  • Qi is -NR1R2, -NR1R11, -NR11R12 or -OR 3 ;
  • Q 2 is optionally substituted alkyl
  • each Ri and R2 is, independently, hydrogen or an amino protecting group
  • each R3 is, independently, hydrogen or a hydroxyl protecting group
  • each R4, R 5 , R 7 and R3 ⁇ 4 is, independently, hydrogen or C1-C6 alkyl optionally substituted with one or more halogen, hydroxyl or amino;
  • each Re is, independently, hydrogen, halogen, hydroxyl, amino or Q-C6 alkyl; or R4 and 5 together with the atoms to which they are attached can form a heterocyclic ring having from 4 to 6 ring atoms, or R5 and one R together with the atoms to which they are attached can form a heterocyclic ring having from 3 to 6 ring atoms, or R and one Re together with the atoms to which they are attached can form a carbocyclic ring having from 3 to 6 ring atoms, or R7 and Re together with the atom to which they are attached can form a heterocyclic ring having from 3 to 6 ring atoms;
  • each n is, independently, an integer from 0 to 4.
  • Zi is hydrogen, halogen or -OR3.
  • each Ri, R 2 and R3 are H.
  • Qi is -NH 2 .
  • Qi is -NHRn.
  • Rn is
  • Rn is substituted Ci-C 6 alkyl, such as, for example, -(CH 2 ) m OH, wherein m is an integer from 1 to 6 (e.g., -(CH 2 ) 3 OH or -(CH 2 ) 2 OH).
  • Qi is -NRnRi 2 .
  • Qi is -OH.
  • Q 2 is:
  • R4 is hydrogen; Rs is hydrogen; and n is an integer from 1 to 4.
  • each Re is hydrogen.
  • Q 2 is:
  • each 3 ⁇ 4 is halogen (such as, for example, fluoro).
  • at least one Rs is hydroxyl.
  • Q2 is:
  • R4 is hydrogen; R 5 and one Re together with the atoms to which they are attached form a heterocyclic ring having from 3 to 6 ring atoms; and n is an integer from 1 to 4.
  • Q 2 is:
  • At least one 3 ⁇ 4 is halog
  • ⁇ 3 ⁇ 4 is:
  • each 3 ⁇ 4 is hydrogen.
  • ⁇ 3 ⁇ 4 is:
  • At least one 3 ⁇ 4 is halogen.
  • (3 ⁇ 4 is:
  • R 5 is hydrogen; R4 and one 3 ⁇ 4 together with the atoms to which they are attached form a carbocyclic ring having from 3 to 6 ring atoms; and n is an integer from 1 to 4.
  • Q2 is:
  • each R6 is hydrogen.
  • ⁇ 3 ⁇ 4 is:
  • R4 and one R « together with the atoms to which they are attached form a carbocyclic ring having from 3 to 6 ring atoms;
  • R7 is hydrogen;
  • Rg is hydrogen;
  • n is an integer from 1 to 4.
  • ( 3 ⁇ 4 is:
  • At least one R « is halogen.
  • Q2 is:
  • R 7 is hydrogen; and Rg is hydrogen.
  • each R6 is hydrogen.
  • ( 3 ⁇ 4 is:
  • At least one R6 is halogen.
  • Q2 is:
  • R 5 is hydrogen.
  • each R$ is hydrogen.
  • at least one R$ is halogen.
  • Q2 is:
  • R 7 is hydrogen; and R3 ⁇ 4 is hydrogen.
  • each Re is hydrogen.
  • at least one R$ is halogen.
  • Q2 is:
  • R 5 is hydrogen.
  • each R3 ⁇ 4 is hydrogen.
  • at least one « is halogen.
  • Q 2 is:
  • R 9 is hydrogen.
  • each Rio is hydrogen.
  • at least one Rio is halogen.
  • Q 2 is:
  • R7 is hydrogen; and Re is hydrogen.
  • each Rio hydrogen.
  • at least one Rio is halogen.
  • Q2 is:
  • each R is hydrogen.
  • at least one Re is halogen.
  • Q2 is unsubstituted or Q 2 is substituted with one or more halogen, hydroxyl or amino.
  • i is H.
  • Zi is -OH.
  • Zi is halogen
  • Qi is -NR1R2, -NR 1 R 11 , -NRi 1 R 12 or -OR 3 ;
  • Q 2 is optionally substituted alkyl,
  • each i and R 2 is, independently, hydrogen or an amino protecting each R 3 is, independently, hydrogen or a hydroxyl protecting group; each R4, R 5 , R 7 and Rg is, independently, hydrogen or C1-C6 alkyl optionally substituted with one or more halogen, hydroxyl or amino;
  • each R6 is, independently, hydrogen, halogen, hydroxyl, amino or Ci-Ce alkyl
  • R5 together with the atoms to which they are attached can form a heterocyclic ring having from 4 to 6 ring atoms
  • R 5 and one R6 together with the atoms to which they are attached can form a heterocyclic ring having from 3 to 6 ring atoms
  • R4 and one R3 ⁇ 4 together with the atoms to which they are attached can form a carbocyclic ring having from 3 to 6 ring atoms
  • R7 and Re together with the atom to which they are attached can form a heterocyclic ring having from 3 to 6 ring atoms;
  • each R is, independently, hydrogen, hydroxyl, amino or C ⁇ -Ce alkyl optionally substituted with one or more halogen, hydroxyl or amino;
  • each Rio is, independently, hydrogen, halogen, hydroxyl, amino or Cj-Ce alkyl
  • each R11 and R12 is, independently, C1-C6 alkyl or substituted C1-C6 alkyl;
  • each n is, independently, an integer from 0 to 4.
  • Zi is hydrogen, halogen or -OR3.
  • each R r , R 2 and R3 are H.
  • Qi is -NH2.
  • Qi is -NHRn.
  • Rn is C1-C6 alkyl, such as, for example, methyl or ethyl.
  • Rn is substituted C1-C6 alkyl, such as, for example, -(CH2) m OH, wherein m is an integer from 1 to 6 (e.g., -(CH 2 ) 3 OH or -(CH 2 ) 2 OH).
  • Qi is -N n .
  • Qi is -OH.
  • Q 2 is:
  • R4 is hydrogen; R 5 is hydrogen; and n is an integer from 1 to 4.
  • each R ⁇ is hydrogen.
  • Q 2 is:
  • At least one Re is halogen.
  • Q 2 is:
  • each 3 ⁇ 4 is halogen (such as, for example, fluoro).
  • at least one 3 ⁇ 4 is hydroxyl.
  • (3 ⁇ 4 is:
  • Q2 is:
  • R4 is hydrogen; R5 and one 3 ⁇ 4 together with the atoms to which they are attached form a heterocyclic ring having from 3 to 6 ring atoms; and n is an integer from 1 to 4.
  • (3 ⁇ 4 is:
  • At least one 3 ⁇ 4 is halogen.
  • (3 ⁇ 4 is:
  • each 3 ⁇ 4 is hydrogen.
  • (3 ⁇ 4 is:
  • At least one 3 ⁇ 4 is halogen.
  • ⁇ 3 ⁇ 4 is:
  • R4 is hydrogen; R7 is hydrogen; Rg is hydrogen; and n is an integer from 1 to 4.
  • each R 3 ⁇ 4 is hydrogen.
  • Q2 is:
  • At least one Re is halogen
  • ⁇ 3 ⁇ 4 is:
  • R4 and one R « together with the atoms to which they are attached form a carbocyclic ring having from 3 to 6 ring atoms;
  • R7 is hydrogen;
  • Rg is hydrogen;
  • n is an integer from 1 to 4.
  • (3 ⁇ 4 is:
  • At least one R 3 ⁇ 4 is halog
  • (3 ⁇ 4 is:
  • R 7 is hydrogen; and R 3 ⁇ 4 is hydrogen.
  • each R is hydrogen.
  • Q2 is:
  • At least one R 3 ⁇ 4 is halogen.
  • Q2 is:
  • each 6 is hydrogen. In other further embodiments, at least one is halogen.
  • Q2 is:
  • R 7 is hydrogen; and Rg is hydrogen.
  • each Re is hydrogen.
  • at least one R3 ⁇ 4 is halogen.
  • (3 ⁇ 4 is:
  • R 5 is hydrogen.
  • each R ⁇ is hydrogen.
  • at least one R ⁇ is halogen.
  • Q2 is:
  • R9 is hydrogen.
  • each io is hydrogen.
  • at least one Rio is halogen.
  • (3 ⁇ 4 is:
  • R 7 is hydrogen; and Rg is hydrogen.
  • each Rio hydrogen.
  • at least one Rio is halogen.
  • ⁇ 3 ⁇ 4 is:
  • R4 is hydrogen.
  • each R « is hydrogen.
  • at least one R « is halogen.
  • Q2 is optionally substituted alkyl.
  • (3 ⁇ 4 is unsubstituted or Q2 is substituted with one or more halogen, hydroxyl or amino.
  • Zi is H.
  • Zi is -OH.
  • Z) is halogen
  • any embodiment of the compounds of structures (I) and (II), as set forth above, and any specific substituent set forth herein for a Qi, (3 ⁇ 4, Ri, 2, R3, R4, R5, Re, R7, e, R3 ⁇ 4 Rio, R-ii, R12 and Zi group in the compounds of structures (I) and (II), as set forth above, may be independently combined with other embodiments and or substituents of compounds of structures (I) and (II) to form embodiments of the inventions not specifically set forth above.
  • compositions of the present invention comprise a compound of structure (I) or (II) and a pharmaceutically acceptable carrier, diluent or excipient.
  • the compound of structure (I) or (II) is present in the composition in an amount which is effective to treat a particular disease or condition of interest - that is, in an amount sufficient to treat a bacterial infection, and preferably with acceptable toxicity to the patient.
  • the antibacterial activity of compounds of structures (I) and (II) can be determined by one skilled in the art, for example, as described in the Examples below. Appropriate concentrations and dosages can be readily determined by one skilled in the art.
  • Compounds of the present invention possess antibacterial activity against a wide spectrum of gram positive and gram negative bacteria, as well as enterobacteria and anaerobes.
  • Representative susceptible organisms generally include those gram positive and gram negative, aerobic and anaerobic organisms whose growth can be inhibited by the compounds of the invention such as Staphylococcus, Lactobacillus, Streptococcus, Sarcina, Escherichia, Enterobacter, Klebsiella, Pseudomonas, Acinetobacter, Mycobacterium, Proteus, Campylobacter, Citrobacter, Nisseria, Baccillus, Bacteroides, Peptococcus, Clostridium, Salmonella, Shigella, Serratia, Haemophilus, Brucella, Francisella, Anthracis, Yersinia, Corynebacterium, Moraxella, Enterococcus, and other organisms.
  • Admimstration of the compounds of the invention, or their pharmaceutically acceptable salts, in pure form or in an appropriate pharmaceutical composition can be carried out via any of the accepted modes of administration of agents for serving similar utilities.
  • the pharmaceutical compositions of the invention can be prepared by combining a compound of the invention with an appropriate pharmaceutically acceptable carrier, diluent or excipient, and may be formulated into preparations in solid, semi-solid, liquid or gaseous forms, such as tablets, capsules, powders, granules, ointments, solutions, suppositories, injections, inhalants, gels, microspheres, and aerosols.
  • compositions of the invention are formulated so as to allow the active ingredients contained therein to be bioavailable upon administration of the composition to a patient.
  • Compositions that will be administered to a subject or patient take the form of one or more dosage units, where for example, a tablet may be a single dosage unit, and a container of a compound of the invention in aerosol form may hold a plurality of dosage units.
  • composition to be administered will, in any event, contain a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, for treatment of a disease or condition of interest in accordance with the teachings of this invention.
  • a pharmaceutical composition of the invention may be in the form of a solid or liquid.
  • the carrier(s) are particulate, so that the compositions are, for example, in tablet or powder form.
  • the carrier(s) may be liquid, with the compositions being, for example, an oral syrup, injectable liquid or an aerosol, which is useful in, for example, inhalatory administration.
  • compositions of the present invention typically are either solid or liquid form, where semi-solid, semi-liquid, suspension and gel forms are included within the forms considered herein as either solid or liquid.
  • the pharmaceutical compositions may be formulated into a powder, granule, compressed tablet, pill, capsule, chewing gum, wafer or the like form.
  • a solid composition will typically contain one or more inert diluents or edible carriers.
  • binders such as carboxymethylcellulose, ethyl cellulose, microcrystalline cellulose, gum tragacanth or gelatin; excipients such as starch, lactose or dextrins, disintegrating agents such as alginic acid, sodium alginate, Primogel, corn starch and the like; lubricants such as magnesium stearate or Sterotex; glidants such as colloidal silicon dioxide; sweetening agents such as sucrose or saccharin; a flavoring agent such as peppermint, methyl salicylate or orange flavoring; and a coloring agent.
  • excipients such as starch, lactose or dextrins, disintegrating agents such as alginic acid, sodium alginate, Primogel, corn starch and the like
  • lubricants such as magnesium stearate or Sterotex
  • glidants such as colloidal silicon dioxide
  • sweetening agents such as sucrose or saccharin
  • a flavoring agent such as peppermint, methyl sal
  • compositions of the invention may be in the form of a liquid, for example, an elixir, syrup, solution, emulsion or suspension.
  • the liquid may be for oral administration or for delivery by injection, as two examples.
  • pharmaceutical compositions of the invention typically contain, in addition to the present compounds, one or more of a sweetening agent, preservatives, dye/colorant and flavor enhancer.
  • a surfactant, preservative, wetting agent, dispersing agent, suspending agent, buffer, stabilizer and isotonic agent may be included.
  • Liquid pharmaceutical compositions of the invention may include one or more of the following adjuvants: sterile diluents such as water for injection, saline solution, preferably physiological saline, Ringer's solution, isotonic sodium chloride, fixed oils such as synthetic mono or diglycerides which may serve as the solvent or suspending medium, polyethylene glycols, glycerin, propylene glycol or other solvents; antibacterial agents such as benzyl alcohol or methyl paraben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose.
  • Parenteral preparations can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
  • Physiological saline is a preferred adjuvant
  • a liquid pharmaceutical composition of the invention intended for either parenteral or oral administration should contain an amount of a compound of the invention such that a suitable dosage will be obtained.
  • compositions of the invention may be intended for topical administration, in which case the carrier may suitably comprise a solution, emulsion, ointment or gel base.
  • the base for example, may comprise one or more of the following: petrolatum, lanolin, polyethylene glycols, bee wax, mineral oil, diluents such as water and alcohol, and emulsifiers and stabilizers.
  • Thickening agents may be present in a pharmaceutical composition for topical administration.
  • the composition may include a transdermal patch or iontophoresis device.
  • compositions of the invention may be intended for rectal administration, in the form, for example, of a suppository, which will melt in the rectum and release the drug.
  • Compositions for rectal administration may contain an oleaginous base as a suitable nonirritating excipient.
  • bases include, without limitation, lanolin, cocoa butter and polyethylene glycol.
  • compositions of the invention may include various materials, which modify the physical form of a solid or liquid dosage unit.
  • the composition may include materials that form a coating shell around the active ingredients.
  • the materials that form the coating shell are typically inert, and may be selected from, for example, sugar, shellac, and other enteric coating agents.
  • the active ingredients may be encased in a gelatin capsule.
  • compositions of the invention in solid or liquid form may include an agent that binds to the compound of the invention and thereby assists in the delivery of the compound.
  • Suitable agents that may act in this capacity include a monoclonal or polyclonal antibody, a protein or a liposome.
  • compositions of the invention may be prepared in dosage units that can be administered as an aerosol.
  • aerosol is used to denote a variety of systems ranging from those of colloidal nature to systems consisting of pressurized packages. Delivery may be by a liquefied or compressed gas or by a suitable pump system that dispenses the active ingredients. Aerosols of compounds of the invention may be delivered in single phase, bi-phasic, or tri-phasic systems in order to deliver the active ingredient(s). Delivery of the aerosol includes the necessary container, activators, valves, subcontainers, and the like, which together may form a kit.
  • compositions of the invention may be prepared by methodology well known in the pharmaceutical art.
  • a pharmaceutical composition intended to be adininistered by injection can be prepared by combining a compound of the invention with sterile, distilled water so as to form a solution.
  • a surfactant may be added to facilitate the formation of a homogeneous solution or suspension.
  • Surfactants are compounds that non-covalently interact with the compound of the invention so as to facilitate dissolution or homogeneous suspension of the compound in the aqueous delivery system.
  • the compounds of the invention are administered in a therapeutically effective amount, which will vary depending upon a variety of factors including the activity of the specific compound employed; the metabolic stability and length of action of the compound; the age, body weight, general health, sex, and diet of the patient; the mode and time of administration; the rate of excretion; the drug combination; the severity of the particular disorder or condition; and the subject undergoing therapy.
  • Compounds of the invention, or pharmaceutically acceptable derivatives thereof, may also be administered simultaneously with, prior to, or after administration of one or more other therapeutic agents.
  • Such combination therapy includes administration of a single pharmaceutical dosage formulation which contains a compound of the invention and one or more additional active agents, as well as administration of the compound of the invention and each active agent in its own separate pharmaceutical dosage formulation.
  • a compound of the invention and the other active agent can be administered to the patient together in a single oral dosage composition such as a tablet or capsule, or each agent administered in separate oral dosage formulations.
  • the compounds of the invention and one or more additional active agents can be administered at essentially the same time, i.e., concurrently, or at separately staggered times, i.e., sequentially; combination therapy is understood to include all these regimens.
  • suitable protecting groups include hydroxy, amino, mercapto and carboxylic acid.
  • suitable protecting groups for hydroxy include trialkylsilyl or diarylalkylsilyl (for example, i-butyldimethylsilyl, t- butyldiphenylsilyl or trimethylsilyl), tetrahydropyranyl, benzyl, and the like
  • suitable protecting groups for amino, amidino and guanidino include f-butoxycarbonyl, benzyloxycarbonyl, and the like.
  • Suitable protecting groups for mercapto include -C(0)-R" (where R" is alkyl, aryl or arylalkyl), p-methoxybenzyl, trityl and the like.
  • Suitable protecting groups for carboxylic acid include alkyl, aryl or arylalkyl esters.
  • Protecting groups may be added or removed in accordance with standard techniques, which are known to one skilled in the art and as described herein. The use of protecting groups is described in detail in Green, T.W. and P.G.M. Wutz, Protective Groups in Organic Synthesis (1999), 3rd Ed., Wiley.
  • the protecting group may also be a polymer resin such as a Wang resin, Rink resin or a 2-chlorotrityl-chloride resin.
  • compounds of the invention which exist in free base or acid form can be converted to their pharmaceutically acceptable salts by treatment with the appropriate inorganic or organic base or acid by methods known to one skilled in the art.
  • Salts of the compounds of the invention can be converted to their free base or acid form by standard techniques.
  • the intermediate compound is, for example:
  • Method A To a stirring solution of the aminoglycoside derivative (0.06 mmol) in MeOH (2 mL) was added the aldehyde (0.068 mmol), silica supported cyanoborohydride (0.1 g, 1.0 mmol/g), and the reaction mixture was heated by microwave irradiation to 100°C (100 watts power) for 15 minutes. The reaction was checked by MS for completeness, and once complete all solvent was removed by rotary evaporation. The resulting residue was dissolved in EtOAc (20 ml), and washed with 5% NaHCC (2 5 mL), followed by brine (5 mL). The organic phase was then dried over Na 2 S0 , filtered and the solvent was removed by rotary evaporation.
  • Method B To a solution of aminoglycoside derivative (0.078 mmol) in DMF (1 ml) were added 3A molecular sieves (15-20), followed by the aldehyde (0.15 mmol) and the reaction was shaken for 2.5 hours. The reaction was checked by MS for completeness and, if needed, more aldehyde (0.5 eq) was added. The reaction mixture was then added dropwise to a stirring solution of NaB3 ⁇ 4 (0.78 mmol) in MeOH (2 mL) at 0°C, and the reaction was stirred for 1 hour. The reaction was diluted with H 2 0 (2 mL) and EtOAc (2 ml). The organic layer was separated and the aqueous layer was extracted with EtOAc (3 x 3 mL). The combined organic layers were dried over Na 2 S04, filtered and concentrated to dryness.
  • Method A To a stirring solution of the Boc protected aminoglycoside (0.054 mmol) in DCM or MeOH (1 mL) were added 3 A molecular sieves (4-6), and trifluoroacetic acid (0.6 mL). The reaction was stirred at room temperature for 1 h, and checked for completeness by MS. Upon completion the reaction mixture was diluted with ether (15 mL) to induce precipitation. The vial was centrifuged and the supernatant was decanted. The precipitate was washed with ether (2 x 15 ml), decanted and dried under vacuum. Procedure 3: PvBOP coupling
  • Procedure 7 N-Boc Protection To a stirring solution of the amine (4.64 mmol) in THF (10 mL) was added IN NaOH (10 mL), followed by Boc-anhydride (5.57 mmol) and the reaction progress was checked by MS. Once complete, the THF was removed by rotary evaporation and water (40 mL) was added. The aqueous phase was separated and extracted with ⁇ 2 0 (2 x 30 ml). The aqueous phase was acidified to pH 3 by the addition of dilute H3PO4 and was then extracted with EtOAc (2 x 60 ml). The combined organic layers were washed with H 2 0 (2 x 30 mL) and brine (30 mL), dried over NaiSO ⁇ filtered and concentrated to dryness.
  • Procedure 8 Syntheses of Epoxides
  • Step # 1 O-(Trimethylsilyl cvanohvdrines: A 50-mL flask equipped with a magnetic stirring bar and drying tube was charged with the ketone or aldehyde (0.010 mmol), followed by THF (50 mL), trimethylsilyl cyanide (1.39 g, 14 mmol), and zinc iodide (0.090 g, 0.28 mmol), and the reaction mixture was stirred at room temperature for 24 hr. Solvent evaporation gave a residue, which was dissolved in EtOAc (60 mL), washed with 5% aq.
  • Step # 2 Acid hydrolysis to a-hvdroxy carboxylic acid: AcOH (25 ml) and cone. HC1 (25 ml) were added to the unpurified material from step #1 and the reaction mixture was refluxed for 2-3 hr. The reaction mixture was then concentrated to dryness to give a white solid, which was carried through to the next step without further purification.
  • Step # 3 Boc protection: To a stirring solution of solid from step #2 in 2 M NaOH (20 mL) and i-PrOH (20 mL) at 0°C was added Boc 2 0 (6.6 g, 3 mmol) in small portions, and the reaction mixture was allowed to warm to room temperature over 4 h. i-PrOH was then evaporated, and 3 ⁇ 40 (50 mL) was added, and the aqueous phase was separated and extracted with Et 2 0 (2 x 30 ml). The aqueous layer was acidified to pH 3 by addition of dilute H 3 P0 4 and was extracted with EtOAc (2 x 60 ml). The combined organic layers were washed with 3 ⁇ 40 (2 x 30 mL) and brine (30 mL), dried over Na 2 S04, filtered and concentrated to yield the desired N-Boc-a-hydroxy carboxylic acids in 56-72% yield.
  • the substrate olefin (0.5 to 0.75 mmol) was dissolved in DCM (30 mL) and the reaction was cooled to -78°C. Ozone was bubbled through until a blue color persisted (3 to 5 min), and the reaction was stirred for 1 hr. Argon was then bubbled through to remove excess ozone for 10 minutes. The reaction was further quenched by the addition of dimethyl sulfide (10 equiv.), and was stirred for 30 min with warming to rt. The solvent was reduced under vacuum to yield the crude aldehyde, which was dried under high- vacuum for 10 min, and used without further purification.
  • N-Boc-4-Methylene-piperidine (0.222 g, 1.12 mmol) was submitted to Procedure 8 to form the desired N-Boc-l-oxa-6-azaspiro[2.5]octane (0.215 g, 1.01 mmol, 90.2% yield): ⁇ NMR (250 MHz, DMSO-d 6 ) ⁇ 3.29-3.61 (m, 6 H), 1.56-1.70 (m, 2 H), 1.30-1.54 (m, 1 1 H).
  • N-Boc-3-pyrrolidone (0.010 mmol) was submitted to Procedure 9 to yield the desired N-Boc-3 -hydroxy-pyrrolidine-3 -carboxylic acid.
  • Procedure 8 for epoxide formation to yield a crude which was purified by flash chromatography (silica gel/hexanes: ethyl acetate 0-45%) to yield N-Boc-2-(oxiran-2- yl)-ethyl carbamate (6.0 g, 0.032 mol, 84.2 % yield): ⁇ NMR (250 MHz, DMSO-d 6 ) ⁇ 2.98-3.09 (m, 2 H), 2.83-2.92 (m, 1 H), 2.65 (t, 1 H), 2.42 (dd, 1 H), 1.44-1.66 (m, 2 H), 1.36 (s, H, (CH 3 ) 3 ).
  • N-Boc-3-azetidinone (21.9 g, 0.128 mol) was submitted to Procedure 9 to yield the desired N-Boc-3-hydroxy-azetidin-3-carboxylic acid (18.7 g, 0.086 mol, 67.0% yield): MS m/e [M+H] + calcd 218.1, found 218.2.
  • N-Boc-3-methylene-cyclobutanamine (1.65 g, 9.0 mmol) was submitted to Procedure 8 for epoxide formation to yield N-Boc-l-oxaspiro[2.3]hexan-5-amine (1.46 g, 7.33 mmol, 81.5 % yield): ⁇ NMR (250 MHz, CDC1 3 ) ⁇ 4.79 (bs, 1 H), 4.13- 4.31 (m, 1 H), 2.66-2.83 (m, 4 H), 2.31-2.47 (m, 2 H), 1.45 (s, 9 H).
  • N-Boc-3-amino-2,2-dimethyl propanol (0.415 g, 2.04 mmol) was submitted to Procedure 11 to yield N-Boc-2,2-dimethyl-3-amino-propionaldehyde (0.39 g, 1.94 mmol, 95.1 % yield): ] H NMR (250 MHz, CDC13) ⁇ 9.42 (s, 1 H), 4.80 (bs, 1 H), 3.11 (d, 2 H), 1.39 (s, 9 H), 1.06 (s, 6 H).
  • N-Boc-3-amino-3-cyclopropyl-propanol (0.130 g, 0.60 mmol) was submitted to Procedure 11 for oxidation to the corresponding N-Boc-3-amino-3- cyclopropyl propionaldehyde, which was carried through to the next step without further purification.
  • N-Boc-l-amino-cyclobutane carboxylic acid (6.28 mmol) was submitted to Procedure 12 for reduction to the corresponding N-Boc-l-Amino-cyclobutyl- methanol.
  • N-Boc-l-amino-cyclobutyl-methanol (0.25 g, 1.24 mmol) was submitted to Procedure 11 to yield the corresponding N-Boc-l-amino-cyclobutane carboxaldehyde (0.24 g, 1.20 mmol, 96.8 % yield): ⁇ NMR (250 MHz, CDC13) ⁇ 9.0 (s, 1 H), 4.91 (bs, 1 H), 3.74 (bs, 2 H), 1.71-2.20 (m, 4 H), 1.42 (s, 9 H).
  • N-Boc-3-amino-cyclobutanone (7.13 g, 38.53 mmol) was submitted to Procedure 9 to yield the desired N-Boc-l-hydroxy-3-amino-cyclobutyl-carboxylic acid (MS m/e [M+H] + calcd 232.1, found 232.2.
  • N, N-diBoc-4(5)-amino-pyrrolidine-2(5)-carboxylic acid (1.03 g, 3.12 mmol) was submitted to Procedure 12 to yield the corresponding N, N-diBoc-4(S)- amino-2(S)-methanol pyrrolidine (0.605 g, 1.91 mmol, 61.2 % yield), which was carried through to the next step without further purification.
  • N, N-diBoc-4(3 ⁇ 4-amino-2(S)-methanol pyrrolidine (0.486 g, 1.53 mmol) was submitted to Procedure 11 for oxidation to the corresponding N, N-diBoc-4(5)- amino-pyrrolidine-2(5)-carbaldehyde, which was carried through to the next step without further purification.
  • N-Boc-l-aminomethyl-cyclopropane carboxylic acid (1.0 g, 4.64 mmol) was submitted to Procedure 12 to yield the corresponding N-Boc-l-aminomethyl- cyclopropyl-methanol (0.99 g, MS m/e [M+H] + calcd 202.1, found 202.1), which was carried through to the next step without further purification.
  • N-Boc-l-aminomethyl-cyclopropane carboxaldehyde N-Boc-l-aminomethyl-cyclopropyl-methanol (0.87 g, 4.32 mmol) was submitted to Procedure 11 for oxidation to the corresponding N-Boc-l-aminomethyl- cyclopropane carboxaldehyde, which was carried through to the next step without further purification.
  • N-Boc-l-amino-cyclopropyl-methanol N-Boc-l-amino-cyclopropane carboxylic acid (0.25 g, 1.24 mmol) was submitted to Procedure 12 to yield the corresponding N-Boc-l-amino-cyclopropyl- methanol (0.051 g, 0.27 mmol, 21.8 % yield), which was carried through to the next step without further purification.
  • N-Boc-l-amino-cyclopropyl-methanol (0.051 g, 0.27 mmol) was submitted to Procedure 11 for oxidation to the corresponding N-Boc-l-amino- cyclopropane carboxaldehyde, which was carried through to the next step without further purification.
  • N-Boc-l(i?)-amino-2(5)-hydroxy-cyclopentane- 4 S -carboxylic acid methyl ester (0.622 g, 2.40 mmol) in DCM (1.9 mL) was added imidazole (0.164 g, 2.41 mmol), DMAP (0.047 g, 0.35 mmmol) and TBSC1 (0.363 g, 2.40 mmol) and the reaction was stirred at room temperature for 18 hours, followed by heating at 40°C for 1 hour. The reaction mixture was cooled to room temperature, and was quenched with 3 ⁇ 40 (3 mL).
  • N-Boc- 1 (/?)-amino-2(S)-iert-butyldimethylsilyloxy-cyclopentane-4(5 - carboxylic acid (0.53 g, 1.47 mmol) was submitted to Procedure 12 for reduction to the corresponding N-Boc- 1 (/?)-amino-2(5)-iert-butyldimethylsilyloxy-4(5)- hydroxymethyl-cyclopentane (0.44 g, 1.27 mmol, 86.4 % yield): ⁇ NMR (250 MHz, CDC1 3 ) ⁇ 4.69-4.79 (m, 1 H), 4.08-4.13 (m, 1 H), 3.88 (bs, 1 H), 3.52-3.61 (m, 2 H), 2.16-2.30 (m, 2 H), 1.96-2.14 (m, 2 H), 1.48-1.53 (m, 2 H), 1.47 (s, 9 H), 0.91 (s, 9 H), 0.09 (s, 6 H).
  • N-Boc-l(ii)-amino-2(S)-3 ⁇ 4rt-butyldimethylsilyloxy-4(5 ⁇ -hydroxymethyl- cyclopentane (0.44 g, 1.27 mmol) was submitted to Procedure 11 for oxidation to the corresponding N-Boc-l( ⁇ )-amino-2(5)- ⁇ ert-butyldimethylsilyloxy-cyclopentane-4(S)- carboxaldehyde (0.42 g, 1.22 mmol, 96.1 % yield).
  • N-Boc-3-(2-hydroxy-ethyl)-azetidin-3-ol (0.29 g, 1.33 mmol) was submitted to Procedure 11 for oxidation to the corresponding 2-(N-Boc-3-hydroxy- azetidin-3-yl)-acetaldehyde, which was carried through to the next step without further purification.
  • N-Boc-azetidine-3-carboxylic acid (1.94 g, 9.64 mmol) was submitted to Procedure 12 for reduction to the corresponding N-Boc-3-hydroxymethyl-azetidine, which was carried through to the next step without further purification.
  • N-Boc-3-hydroxymethyl-azetidine (9.64 mmol) was submitted to Procedure 11 for oxidation to the desired N-Boc-azetidine-3-carboxaldehyde, which was carried through to the next step without further purification.
  • Penta-l,4-dienol (5 g, 59.4 mmol) and excess cumene hydroperoxide (80%, 17.5 mL) were added in small portions, and stirring was continued at -35°C for 48 hr. The reaction was quenched by addition of sat. aq. Na 2 S0 4 (5 mL) immediately followed by Et 2 0 (50 mL) and the
  • ⁇ -Methyl morpholine (1.41 mL, 12.9 mmol) was added dropwise, and the reaction was stirred at -15°C for 2 hr. The reaction was quenched with phosphate buffer (0.1 M, pH 6.0) and the aqueous layer was 5 separated. The organic layer was washed with the phosphate buffer (3 x), dried over Na2SC filtered and reduced under vacuum to give a brown residue.
  • phosphate buffer 0.1 M, pH 6.0
  • the resulting solution was stirred for 20 min, then sodium hydride (9.2 g, 228 mmol, 1.1 equiv, 60% mineral oil dispersion) was added to the batch in portions such that the batch temperature was maintained at -10 to -15 °C. Once the addition of sodium hydride was complete, the reaction mixture was stirred for additional 30 min and then brought to ambient temperature and further stirred for 18 h. The reaction was quenched with aqueous NaHC0 3 (280 mL) while maintaining the reaction mixture at -5 to 0 °C (ice bath). The reaction mixture was then diluted with MTBE (1.4 L mL) and the phases separated.
  • sodium hydride 9.2 g, 228 mmol, 1.1 equiv, 60% mineral oil dispersion
  • the reaction mixture was concentrated under reduced pressure and further dried under high vacuum to obtain the crude aldehyde 4, as a thick oil (35.5 g, >99%).
  • R f 0.38 (1:1 MTBE/heptanes).
  • the reaction was repeated at 30 g scale of 3 to afford crude aldehyde 4 (33.4 g, >99%).
  • the two lots of crude aldehyde were combined and subjected to the Pinnick oxidation without further purification.
  • the crude aldehyde 4 (30.1 g) was taken into a mixture of tetrahydrofuran, iBuOH, and water (226 mL, 226 mL, 151 mL, 3:3:2) along with NaH 2 P0 4 (33.7 g, 281 mmol) and 2-methyl-2-butene (149 mL, 1.4 mol).
  • the solution was cooled (15 ⁇ 5 °C, water bath).
  • Sodium chlorite (12.7 g, 140 mmol) was added to the batch and the resulting solution was stirred at ambient temperature for 4 hr. The completion of the reaction was confirmed by TLC analysis (1:1 MTBE/heptanes and 5% MeOH in DCM).
  • reaction mixture was then concentrated in vacuo to a yellow solid residue, removing all excess methylamine.
  • the residue was taken up in THF (700 mL) and water (350 mL), cooled to 0 - 5 °C, and to the crude amino acid solution was added potassium carbonate (45 g, 326 mmol), followed by benzylchloroformate (17.2 mL, 114 mmol).
  • the batch was warmed to ambient temperature and the reaction allowed to proceed for 28 hours. Analysis of an aliquot at this time point by LCMS indicated a complete conversion of the amino acid to the carbamate.
  • the reaction mixture was concentrated under reduced pressure to remove most of THF, the aqueous residue was diluted with water (320 mL) and the pH adjusted with 2N HC1 to approximately pH 5 (pH paper strip).
  • the crude product was extracted with methylene chloride (3 x 500 mL), the extracts washed with water (60 mL), brine (60 mL), dried (MgS0 4 ), and concentrated in vacuo to a yellow oil (40.34 g) which was purified by flash column chromatography on silica gel (400 g; elution with 0 - 5% MeOH in CH 2 CI 2 ) to afford compound 6 as a yellow oil (27.5 g, 92% yield over two steps).
  • reaction was carried out at 20-g scale of alcohol following a 20 literature procedure (J. Org. Chem. 2009, 74(15), 5758-5761).
  • a 2-L round-bottomed flask equipped with a mechanical stirrer, a thermocouple probe, and an addition funnel was charged with a solution of epoxy alcohol ent-2 [20 g, 200 mmol, 1 equiv] in tetrahydrofuran (400 mL, 20 vol) along with Ph 3 P (105 g, 400 mmol, 2 equiv), and 4- nitrobenzoic acid (67 g, 400 mmol, 2 equiv) under a nitrogen atmosphere.
  • DIAD (81 g, 25 400 mmol, 2 equiv) was added to the reaction mixture using an addition funnel while maintaining the reaction mixture at 0 °C (ice bath). Once the addition of DIAD was complete, the cold bath was removed and the reaction mixture was allowed to come to ambient temperature (23 °C). The reaction mixture was stirred for 1.5 h (all starting material consumed) and then quenched with aqueous NaHCC solution (100 ml, 5 vol) 30 followed by the addition of MTBE (1000 mL, 50 vol). The resulting solution was transferred into a separatory funnel. Brine (100 mL, 5 vol) was added to obtain phase separation.
  • the reaction mixture was concentrated on a rotary evaporator (at ambient water bath temperature) to ⁇ 2 vol (45 mL).
  • the thick solution was then reslurried in DCM (454 mL, 20 vol).
  • the slurry was filtered and the solids were washed with DCM (2 5 vol, 2 114 mL).
  • the combined organic filtrate was dried (MgSC ), filtered, and concentrated to obtain a solid (31 g).
  • Sodium hydride (4.1 g, 1.1 equiv, 60% mineral oil dispersion) was then added to the batch in portions such that the batch temperature was maintained at -10 to -15 °C. Once the addition of sodium hydride was complete, the reaction mixture was stirred for an additional 30 min and then the cold bath was removed and reaction mixture brought up to ambient temperature and further stirred for 18 h. The reaction was quenched with aqueous NaHC03 (37 mL, 4 vol) while maintaining the temperature at -5 to 0 °C (ice bath).
  • the resulting solution was stirred for 20 min, then sodium hydride (1.97 g, 1.1 equiv, 60% mineral oil dispersion) was added to the batch in portions such that the batch temperature was maintained at -10 to -15 °C. Once the addition of sodium hydride was complete, the reaction mixture was stirred for an additional 30 min and then brought to ambient temperature and further stirred for 18 h. The reaction was quenched with aqueous NaHC(3 ⁇ 4 (60 mL, 4 vol) while maintaining the reaction mixture at -5 to 0 °C (ice bath). The reaction mixture was then diluted with MTBE (300 mL, 20 vol) and the phases separated.
  • the reaction was repeated at 13 g scale of 6. The two lots of crude aldehyde were combined and subjected to the Pinnick oxidation without further purification.
  • the crude aldehyde 7 [14.06 g], was taken into a mixture of tetrahydrofuran, iBuOH, and water (105 mL, 105 mL, 70 mL, 3:3:2, 20 vol) along with NaH 2 P0 (15.6 g, 130 mmol, 4 equiv) and 2-methyl-2-butene (34.4 mL, 324 mmol, 10 equiv). The solution was cooled (15 ⁇ 5 °C, water bath). Sodium chlorite (3.9 g, 43 mmol, 1.33 equiv) was added to the batch and the resulting solution was stirred at ambient temperature for 4 nr.
  • the reaction mixture was then concentrated in vacuo to a yellow solid residue, removing all excess methylamine.
  • the residue was taken up in THF (60 mL, 24 vol) and water (30 mL, 12 vol), cooled to 0 - 5 °C, and to the crude amino acid solution was added potassium carbonate (3.9 g, 28.26 mmol, 5.0 equiv), followed by benzylchloroformate (1.4 mL, 9.81 mmol, 1.75 equiv).
  • the batch was warmed to ambient temperature and the reaction allowed to proceed for 25.5 hours. Analysis of an aliquot at this time point by LCMS indicated a complete conversion of the amino acid to the carbamate.
  • the reaction mixture was concentrated under reduced pressure to remove most of THF, the aqueous residue was diluted with water (30 mL, 12 vol) and the pH adjusted with 2N HC1 to approximately pH 5 (pH paper strip).
  • the crude product was extracted with chloroform (3 x 60 mL), the extracts washed with water (1 x 60 mL) and with aqueous NaCl (1 x 60 mL), dried (MgS0 4 ) and concentrated in vacuo to a yellow, mobile oil (3.52 g) which was purified by flash column chromatography on silica gel (50 wt.
  • ester 1 (4.00 g, 34.4 mmol) and triethylamine (4.79 mL, 34.4 mmol) in anhydrous dichloromethane (170 mL) was cooled to 0 °C under nitrogen and ieri-butyldimethylsilyltrifluoromethane sulfonate (8.31 mL, 36.2 mmol) was added dropwise. The resulting solution was stirred vigorously at reflux for 4 h. The solvent was then carefully evaporated, the residue was dissolved in ⁇ 3 ⁇ 40 (170 mL), and the organic phase was washed with water (3 ⁇ 50 mL). The organic phase was driedNa2SC>4), filtered, and concentrated.
  • reaction mixture was then purified on a 1-inch reverse phase HPLC column (Method 2) to yield 17 (MS m/z calcd for C 7 5H8 9 7 027 (M+Na ⁇ 1542.6, found 1542.6), and 18 (MS m/z calcd for C 75 H 89 N 7 027 (M+Na + ) 1542.6, found 1542.6).
  • the reaction mixture was acidified with HFBA, and was purified on a 1-inch reverse phase HPLC (0.1% HFBA/3 ⁇ 40 and 0.1% HFBA/CH 3 CN), followed by purification on a 1-inch reverse phase HPLC column (50 mM NH 4 OH/ H 2 0 and 50 mM NH 4 OH/CH 3 CN) to yield 4 (21mg, 0.029 mmol, 30% yield): MS m/z calcd for C 2 7H5 3 N 7 Oi5 (M+H 4 ) 716.4 found 716.1 CLND 100% purity.
  • Paromomycin sulfate (6, 685 g free base, 1113 mmol) was dissolved in water (4 L) and then ACN (4 L) was slowly added to the reaction. The reaction was cooled to 0°C and then DIPEA (1525 mL, 8910 mmol) was added. O-Cbz-2- nitrophenol (5, 304 g, 1113 mmol) was dissolved in ACN (1 L) and added to the reaction via an addition funnel in one hour.
  • paromomycin sulfate 1 (76 g, 84 mmol) in 3 ⁇ 40 (209 mL) and THF (1084 mL) at 0 C C was added an aqueous solution of sodium carbonate (254 mL, 218 mmol, 0.86 M), followed by the dropwise addition of benzyl chloroformate (120 mL, 840 mmol). NaHC0 3 (70.6 g, 840 mmol) was then added and the reaction was stirred for 3 hr. The organic layer was separated and concentrated (to about 800 mL), diluted with EtOAc (400 mL) and dripped into hexane (9 L).
  • Zinc chloride (59.2 g, 434 mmol) was dissolved in benzaldehyde (440 mL, 4344 mmol) to give a yellow solution, and the reaction was stirred for 5 min. A solution of 2 (69.85 g, 54.3 mmol) in benzaldehyde (440 mL) was then added and the reaction was stirred for 7 hr. The reaction mixture was diluted with EtOAc (2 L) and washed with 0.1M EDTA disodium salt dihydrate (3 x 2L), H 2 0 (2 L), brine (2 L), dried over Na 2 S0 4 , concentrated (to about 900mL) and dripped into Et 2 0: hexane (1:1, 4 L).
  • the reaction was quenched with the addition of 3-(dimethylamino)-propylamine (148 mL, 1.174 mole), and diluted with EtOAc (1 L) and 3 ⁇ 40 (1 L).
  • the reaction mixture was partitioned between EtOAc (1 L) and 1M citric acid (2 L)/brine (1 L).
  • the aqueous layer was diluted with brine (500 mL) and extracted with EtOAc (500 mL).
  • the combined organic layers were washed with 1 M citric acid (1 L), brine (500 mL).
  • the organic layer was then stirred with saturated NaHC(1 ⁇ 2 (2 L) and 3 ⁇ 40 (600 mL) until off-gassing ceased.
  • Neomycin sulfate (1, 240 g, 391 mmol) was suspended in MeOH (10 L), diluted with H 2 0 (400 mL), cooled to 0°C, and K 2 C0 3 (1080 g, 7818 mmol) was slowly added.
  • Benzyl chloroformate (550 mL, 3910 mmol) was then added to the reaction mixture via a dropping funnel over 3 hours. The mixture was stirred vigorously for 18 hours at room temperature, then was filtered and concentrated (to 2 L).
  • Citric acid (1 M, 100 mL) was then added, followed by brine (500 mL), and the aqueous layer was extracted with EtOAc (500 mL). The organic layer was washed with 1M citric acid (500 mL), sat. aq.

Abstract

L'invention concerne des composés ayant une activité antibactérienne. Les composés ont une des structures (I) ou (II) suivantes : y compris leurs stéréoisomères, sels pharmaceutiquement acceptables et promédicaments, dans lesquelles Q1, Q2, R1, R2, R3 et Z1 sont tels que définis dans le présent document. Des procédés associés avec la préparation et l'utilisation de tels composés, ainsi que des compositions pharmaceutiques comprenant de tels composés, sont également décrits.
PCT/US2010/052109 2009-10-09 2010-10-08 Analogues d'aminoglycoside antibactériens WO2011044538A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25010409P 2009-10-09 2009-10-09
US61/250,104 2009-10-09

Publications (2)

Publication Number Publication Date
WO2011044538A1 true WO2011044538A1 (fr) 2011-04-14
WO2011044538A9 WO2011044538A9 (fr) 2012-01-05

Family

ID=43499037

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/052109 WO2011044538A1 (fr) 2009-10-09 2010-10-08 Analogues d'aminoglycoside antibactériens

Country Status (1)

Country Link
WO (1) WO2011044538A1 (fr)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8114856B2 (en) 2005-12-02 2012-02-14 Isis Pharmaceuticals, Inc. Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents
WO2012067978A1 (fr) * 2010-11-17 2012-05-24 Achaogen, Inc. Analogues d'aminoglycosides antibactériens
US8367625B2 (en) 2008-10-09 2013-02-05 Achaogen, Inc. Antibacterial aminoglycoside analogs
US8372813B2 (en) 2008-10-09 2013-02-12 Achaogen, Inc. Antibacterial aminoglycoside analogs
US8377896B2 (en) 2008-09-10 2013-02-19 Isis Pharmaceuticals, Inc Antibacterial 4,6-substituted 6′, 6″ and 1 modified aminoglycoside analogs
US8383596B2 (en) 2007-11-21 2013-02-26 Achaogen, Inc. Antibacterial aminoglycoside analogs
US8399419B2 (en) 2008-09-10 2013-03-19 Achaogen, Inc. Antibacterial aminoglycoside analogs
US8481502B2 (en) 2009-10-09 2013-07-09 Achaogen, Inc. Antibacterial aminoglycoside analogs
CN103204887A (zh) * 2013-04-11 2013-07-17 北京化工大学 地贝卡星及阿贝卡星的合成方法
US8492354B2 (en) 2009-05-15 2013-07-23 Achaogen, Inc. Antibacterial aminoglycoside analogs
US8524689B2 (en) 2009-05-15 2013-09-03 Achaogen, Inc. Antibacterial aminoglycoside analogs
US8524675B2 (en) 2009-05-15 2013-09-03 Achaogen, Inc. Antibacterial aminoglycoside analogs
US8653042B2 (en) 2009-05-15 2014-02-18 Achaogen, Inc. Antibacterial aminoglycoside analogs
US8658606B2 (en) 2009-05-15 2014-02-25 Achaogen, Inc. Antibacterial aminoglycoside analogs
WO2017037718A1 (fr) * 2015-09-02 2017-03-09 Eloxx Pharmaceuticals Ltd. Dérivés d'aminoglycoside et leurs utilisations dans le traitement de troubles génétiques
WO2018167794A1 (fr) * 2017-03-15 2018-09-20 Eloxx Pharmaceuticals Ltd. Préparation à grande échelle d'aminoglycosides de pseudo-trisaccharides et d'intermédiaires de ceux-ci
US10899785B2 (en) 2015-09-02 2021-01-26 Eloxx Pharmaceuticals Ltd. Aminoglycoside derivatives and uses thereof in treating genetic disorders
US11306115B2 (en) 2015-09-02 2022-04-19 Eloxx Pharmaceuticals Ltd. Aminoglycoside derivatives and uses thereof in treating genetic disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0021150A1 (fr) * 1979-06-07 1981-01-07 FARMITALIA CARLO ERBA S.p.A. Dérivés de la paromomycine, procédé pour leur préparation et composition thérapeutique les contenant
WO2003059246A2 (fr) * 2001-12-26 2003-07-24 Yeda Research And Development Co.Ltd. Procedes d'utilisation de conjugues de saccharides et de composes d'acetamidine ou de guanidine pour le traitement d'infections bacteriennes
WO2007064954A2 (fr) * 2005-12-02 2007-06-07 Isis Pharmaceuticals, Inc. Analogues d'aminoglycoside 4,5-substitués antibactériens comportant plusieurs substituants
WO2008124821A1 (fr) * 2007-04-10 2008-10-16 Achaogen Inc. Analogues de l'aminoglycoside 1,4,5-substitué antibactérien

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0021150A1 (fr) * 1979-06-07 1981-01-07 FARMITALIA CARLO ERBA S.p.A. Dérivés de la paromomycine, procédé pour leur préparation et composition thérapeutique les contenant
WO2003059246A2 (fr) * 2001-12-26 2003-07-24 Yeda Research And Development Co.Ltd. Procedes d'utilisation de conjugues de saccharides et de composes d'acetamidine ou de guanidine pour le traitement d'infections bacteriennes
WO2007064954A2 (fr) * 2005-12-02 2007-06-07 Isis Pharmaceuticals, Inc. Analogues d'aminoglycoside 4,5-substitués antibactériens comportant plusieurs substituants
WO2008124821A1 (fr) * 2007-04-10 2008-10-16 Achaogen Inc. Analogues de l'aminoglycoside 1,4,5-substitué antibactérien

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
"Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", December 2000, WILEY
"Remington: The Science and Practice. of Pharmacy", 2000, PHILADELPHIA COLLEGE OF PHARMACY AND SCIENCE
AGRAWAL ET AL.: "Protocols for Oligonucleotide Conjugates", vol. 26, 1994, HUMANA PRESS, pages: 1 - 72
ALPER, P.B.; HENDRIX, M.; SEARS, P.; WONG, C., J AM. CHEM. SOC., vol. 120, 1998, pages 1965
BUNDGARD, H.: "Design of Prodrugs", 1985, ELSEVIER, pages: 7 - 9,21-24
CHOW, C.S.; BOGDAN, F.M., CHEM. REV., vol. 97, 1997, pages 1489
GREEN, T.W.; P.G.M. WUTZ: "Protective Groups in Organic Synthesis", 1999, WILEY
GREENE; WUTS: "Protective Groups in Organic Synthesis", 1999, JOHN WILEY & SONS
HANESSIAN S.; TAKAMOTO T.; MASSE R.; PATIL G.: "Aminoglycoside antibiotics: Chemical conversion of neomycin B, paromomycin, and lividomycin B into bioactive pseudosaccharides", CAN. J. CHEM., vol. 56, 1978, pages 1482
HANESSIAN, S. ET AL.: "probing the ribosomalRNA A-site with functionally diverse analogues of paromomycin - synthesis of ring I mimetics", TETRAHEDRON, vol. 63, 2007, pages 827 - 846, XP002620224 *
HIGUCHI, T. ET AL.: "Bioreversible Carriers in Drug Design", vol. 14, 1987, AMERICAN PHARMACEUTICAL ASSOCIATION AND PERGAMON PRESS
J. ORG. CHEM., vol. 74, no. 15, 2009, pages 5758 - 5761
MOAZED, D.; NOLLER, H.F., NATURE, vol. 327, 1987, pages 389
WALLIS, M.G.; SCHROEDER, R, PROG. BIOPHYS. MOLEC. BIOL., vol. 67, 1997, pages 141

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8114856B2 (en) 2005-12-02 2012-02-14 Isis Pharmaceuticals, Inc. Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents
US8569264B2 (en) 2005-12-02 2013-10-29 Isis Pharmaceuticals, Inc. Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents
US11117915B2 (en) 2007-11-21 2021-09-14 Cipla USA, Inc. Antibacterial aminoglycoside analogs
US9688711B2 (en) 2007-11-21 2017-06-27 Achaogen, Inc. Antibacterial aminoglycoside analogs
US9266919B2 (en) 2007-11-21 2016-02-23 Achaogen, Inc. Antibacterial aminoglycoside analogs
US8822424B2 (en) 2007-11-21 2014-09-02 Achaogen, Inc. Antibacterial aminoglycoside analogs
US8383596B2 (en) 2007-11-21 2013-02-26 Achaogen, Inc. Antibacterial aminoglycoside analogs
US8399419B2 (en) 2008-09-10 2013-03-19 Achaogen, Inc. Antibacterial aminoglycoside analogs
US8377896B2 (en) 2008-09-10 2013-02-19 Isis Pharmaceuticals, Inc Antibacterial 4,6-substituted 6′, 6″ and 1 modified aminoglycoside analogs
US8367625B2 (en) 2008-10-09 2013-02-05 Achaogen, Inc. Antibacterial aminoglycoside analogs
US8372813B2 (en) 2008-10-09 2013-02-12 Achaogen, Inc. Antibacterial aminoglycoside analogs
USRE47741E1 (en) 2009-05-15 2019-11-26 Achaogen, Inc. Antibacterial aminoglycoside analogs
US8524689B2 (en) 2009-05-15 2013-09-03 Achaogen, Inc. Antibacterial aminoglycoside analogs
US8653042B2 (en) 2009-05-15 2014-02-18 Achaogen, Inc. Antibacterial aminoglycoside analogs
US8658606B2 (en) 2009-05-15 2014-02-25 Achaogen, Inc. Antibacterial aminoglycoside analogs
US8492354B2 (en) 2009-05-15 2013-07-23 Achaogen, Inc. Antibacterial aminoglycoside analogs
US8524675B2 (en) 2009-05-15 2013-09-03 Achaogen, Inc. Antibacterial aminoglycoside analogs
US8481502B2 (en) 2009-10-09 2013-07-09 Achaogen, Inc. Antibacterial aminoglycoside analogs
US8653041B2 (en) 2010-11-17 2014-02-18 Achaogen, Inc. Antibacterial aminoglycoside analogs
US8318685B2 (en) 2010-11-17 2012-11-27 Achaogen, Inc. Antibacterial aminoglycoside analogs
WO2012067978A1 (fr) * 2010-11-17 2012-05-24 Achaogen, Inc. Analogues d'aminoglycosides antibactériens
WO2014166139A1 (fr) * 2013-04-11 2014-10-16 北京化工大学 Procédé de synthèse de dibékacine et d'arbékacine
CN103204887A (zh) * 2013-04-11 2013-07-17 北京化工大学 地贝卡星及阿贝卡星的合成方法
WO2017037718A1 (fr) * 2015-09-02 2017-03-09 Eloxx Pharmaceuticals Ltd. Dérivés d'aminoglycoside et leurs utilisations dans le traitement de troubles génétiques
US10786520B2 (en) 2015-09-02 2020-09-29 Eloxx Pharmaceuticals Ltd. Aminoglycoside derivatives and uses thereof in treating genetic disorders
US10899785B2 (en) 2015-09-02 2021-01-26 Eloxx Pharmaceuticals Ltd. Aminoglycoside derivatives and uses thereof in treating genetic disorders
US11306115B2 (en) 2015-09-02 2022-04-19 Eloxx Pharmaceuticals Ltd. Aminoglycoside derivatives and uses thereof in treating genetic disorders
US11613551B2 (en) 2015-09-02 2023-03-28 Eloxx Pharmaceuticals Ltd. Aminoglycoside derivatives and uses thereof in treating genetic disorders
IL269364A (en) * 2017-03-15 2019-11-28 Eloxx Pharmaceuticals Ltd A process for the large-scale production of tricyclic aminoglycosides and their intermediates
WO2018167794A1 (fr) * 2017-03-15 2018-09-20 Eloxx Pharmaceuticals Ltd. Préparation à grande échelle d'aminoglycosides de pseudo-trisaccharides et d'intermédiaires de ceux-ci
US11136345B2 (en) 2017-03-15 2021-10-05 Eloxx Pharmaceuticals Ltd. Large scale preparation of pseudo-trisaccharide aminoglycosides and of intermediates thereof

Also Published As

Publication number Publication date
WO2011044538A9 (fr) 2012-01-05

Similar Documents

Publication Publication Date Title
USRE47741E1 (en) Antibacterial aminoglycoside analogs
WO2011044538A1 (fr) Analogues d'aminoglycoside antibactériens
US8481502B2 (en) Antibacterial aminoglycoside analogs
DK2217610T3 (en) ANTIBACTERIAL AMINOGLYCOSIDE ANALOGICAL COMPOUNDS
US8372813B2 (en) Antibacterial aminoglycoside analogs
US8658606B2 (en) Antibacterial aminoglycoside analogs
US8524675B2 (en) Antibacterial aminoglycoside analogs
US8367625B2 (en) Antibacterial aminoglycoside analogs
US8653042B2 (en) Antibacterial aminoglycoside analogs
WO2011044503A1 (fr) Analogues d'aminoglycoside antibactériens
US8524689B2 (en) Antibacterial aminoglycoside analogs
WO2011044498A1 (fr) Analogues antibactériens d'aminoglycosides
WO2011044502A1 (fr) Analogues d'aminoglycoside antibactériens

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10766199

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WPC Withdrawal of priority claims after completion of the technical preparations for international publication

Ref document number: 61/250,104

Country of ref document: US

Date of ref document: 20120322

Free format text: WITHDRAWN AFTER TECHNICAL PREPARATION FINISHED

122 Ep: pct application non-entry in european phase

Ref document number: 10766199

Country of ref document: EP

Kind code of ref document: A1